secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2025-08-01T23:59:59+00:00
Accession:  0001104659-25-072900
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel completes enrollment (last patient last visit) in SERENITY At-Home Phase 3 trial for BXCL501
--------------------------------------------------------------------------------

- SERENITY At-Home Phase 3 safety trial for BXCL501 120 mcg to treat acute agitation in bipolar/schizophrenia.
- Enrolled >200 patients across 22 sites; no single site >11% of total patients.
- Patient distribution balanced between bipolar disorders and schizophrenia.
- Collected data from >2,200 agitation episodes; topline results expected in August 2025.
- Topline results expected to be announced this month.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925072900/0001104659-25-072900-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925072900/tm2522315d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-072900

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer